US 2011/0257891 A1Published application

Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis

AssigneesBaxter Healthcare S.A., Baxter International Inc.

InventorsAlp Akonur, John Kenneth Leypoldt, Ying-Cheng Lo, Baris Ugar Agar

Life of this patent

Estimating the term…

Loading patent…

Abstract

A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

Claims50

Dependent claims

A method of predicting serum phosphorus concentrations in a patient during hemodialysis, the method comprising:

measuring serum phosphorus concentrations (“C”) of the patient over a hemodialysis treatment session time and an ultrafiltration rate (“QUF”) calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session;
estimating KM and VPRE for the patient using a non-linear least squares fitting to the equations:
C

(
t
)
=
C
PRE
[
K
M
+
(
K
D
+
K
R
-
Q
UF
)

(
V

(
t
)
V
PRE
)
K
M
+
K
D
+
K
R
-
Q
UF
Q
UF
K
M
+
K
D
+
K
R
-
Q
UF
]



and
(
eqn
.

1

-

A
)

C

(
T
)
=
C
PRE
-
(
C
PRE
-
C
POST
)


(
-
K
M

T
V
PRE
-
Q
UF
)
(
eqn
.

1

-

B
)
wherein t is a time during the hemodialysis treatment session,
T is a time after an end of the hemodialysis treatment session,
ttx is a total duration of the hemodialysis treatment session,
CPRE is a pre-dialysis plasma phosphorus concentration,
CPOST is a post-dialytic plasma phosphorus concentration,
KM is a phosphorus mobilization clearance of the patient,
KR is a residual renal clearance of phosphate,
KD is a dialyzer phosphate clearance,
VPRE is a pre-dialysis distribution volume of phosphorus of the patient, and
V(t)=VPRE−QUF×t (eqn. 1-C);
and
predicting C of the patient at any time during any hemodialysis treatment session by using the equations 1-A and 1-B with the estimated KM and VPRE of the patient.

123 more elements

A method of predicting serum phosphorus concentrations in a patient during hemodialysis, the method comprising:

measuring serum phosphorus concentrations (“C”) of the patient over a hemodialysis treatment session time for an ultrafiltration rate (“QUF”)=0 during an initial hemodialysis treatment session;
estimating KM and VPRE for the patient using a non-linear least squares fitting to the equations:
C

(
t
)
=
C
PRE
[
K
M
+
(
K
D
+
K
R
)


-
t

(
K
M
+
K
D
+
K
R
)
V
PRE
K
M
+
K
D
+
K
R
]



and
(
eqn
.

2

-

A
)
C

(
T
)
=
C
PRE
-
(
C
PRE
-
C
POST
)


(
-
K
M

T
V
PRE
)
(
eqn
.

2

-

B
)
wherein t is a time during the hemodialysis treatment session,
T is a time after an end of the hemodialysis treatment session,
ttx is a total duration of the hemodialysis treatment session,
CPRE is a pre-dialysis plasma phosphorus concentration,
CPOST is a post-dialytic plasma phosphorus concentration,
KM is a phosphorus mobilization clearance of the patient,
KR is a residual renal clearance of phosphate,
KD is a dialyzer phosphate clearance, and
VPRE is a pre-dialysis distribution volume of phosphorus of the patient;
and
predicting C of the patient at any time during any hemodialysis treatment session by using the equations 2-A and 2-B with the estimated KM and VPRE of the patient.

106 more elements

A computing device comprising:

a display device;
an input device;
a processor;
and
a memory device that stores a plurality of instructions, which when executed by the processor, cause the processor to operate with the display device and the input device to:
(a) receive data relating to serum phosphorus concentrations (“C”) of a hemodialysis patient over a hemodialysis treatment session time and an ultrafiltration rate (“QUF”) calculated by a difference between pre- and post-dialytic body weight of the hemodialysis patient during a hemodialysis treatment session divided by a total treatment time of the treatment session;
(b) estimate KM and VPRE for the patient using a non-linear least squares fitting to the equations:
C

(
t
)
=
C
PRE
[
K
M
+
(
K
D
+
K
R
-
Q
UF
)

(
V

(
t
)
V
PRE
)
K
M
+
K
D
+
K
R
-
Q
UF
Q
UF
K
M
+
K
D
+
K
R
-
Q
UF
]

and
(
eqn
.

3

-

A
)

C

(
T
)
=
C
PRE
-
(
C
PRE
-
C
POST
)


(
-
K
M

T
V
PRE
-
Q
UF

t
tx
)
(
eqn
.

3

-

B
)
wherein t is a time during the hemodialysis treatment session,
T is a time after an end of the hemodialysis treatment session,
ttx is a total duration of the hemodialysis treatment session,
CPRE is a pre-dialysis plasma phosphorus concentration,
CPOST is a post-dialytic plasma phosphorus concentration,
KM is a phosphorus mobilization clearance of the patient,
KR is a residual renal clearance of phosphate,
KD is a dialyzer phosphate clearance,
VPRE is a pre-dialysis distribution volume of phosphorus of the hemodialysis patient, and
(c) predict C of the patient at any time during hemodialysis by using the equation 3-A and the estimated KM and VPRE of the patient.

127 more elements

A method of determining steady state, pre-dialysis serum phosphorus levels in a hemodialysis patient, the method comprising:

obtaining a net generation of phosphorus (“G”) of the hemodialysis patient;
determining steady state, pre-dialysis serum phosphorus levels (“CSS-PRE”) of the hemodialysis patient using the equation:
C
SS
-
PRE
=
(
G
)

(
10080
/
F
)
(
K
D
+
K
R
)

n

C
_
tx

t
tx
+
K
R

n

C
_
i

(
10080
/
F
-
t
tx
)
(
eqn
.

4

-

A
)
wherein F is a frequency of treatments per week,
ttx is a treatment time for one hemodialysis treatment session,
KD is a dialyzer phosphate clearance,
KR is a residual renal clearance of phosphate,
n Ctx is the normalized time averaged plasma phosphorus concentration during a dialysis treatment, and
n Ci is the normalized time averaged plasma phosphorus concentration for an interdialytic interval;
and
simulating the effect of at least one of a patient parameter or a treatment parameter on CSS-PRE of the hemodialysis patient.

65 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/088,044Filed 15 Apr 2011
Priority: 16 Apr 2010
Published: 20 Oct 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61M 1/1603
Control or regulation: regulation parameters
A61M 1/16
Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for…:…
A61M 1/1611
Regulation parameters: weight of the patient
A61M 1/1613
Control or regulation: profiling or modelling of patient or predicted treatment evolution or outcome

Family

Application61/325,113Us provisional application · filed 16 Apr 2010
Application61/388,315Us provisional application · filed 30 Sep 2010
Application61/438,002Us provisional application · filed 31 Jan 2011
US 8,868,350 B2Related patent
US 2011/0257891 A1This patent

From the US filing history. Foreign family members aren’t listed.